S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
OTCMKTS:ISCO

International Stem Cell Stock Forecast, Price & News

$0.56
+0.03 (+5.66 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.54
$0.56
50-Day Range
$0.48
$0.62
52-Week Range
$0.30
$1.08
Volume7,856 shs
Average Volume11,755 shs
Market Capitalization$4.48 million
P/E RatioN/A
Dividend YieldN/A
Beta0.76
30 days | 90 days | 365 days | Advanced Chart
Receive ISCO News and Ratings via Email

Sign-up to receive the latest news and ratings for International Stem Cell and its competitors with MarketBeat's FREE daily newsletter.


International Stem Cell logo

About International Stem Cell

International Stem Cell Corp. operates as a clinical stage biotechnology company. The firm engages in the development of therapeutic and biomedical products. It operates through the following segments: Cosmetic Market, Biomedical Market and Therapeutic Market. The Cosmetic Market segment develops, manufactures and markets a cosmetic skin care products based on the company's proprietary parthenogenetic stem cell technology and targeted small molecule technology. The Biomedical Market segment involves in the development, manufacture and commercialization of primary human cell research products. The Therapeutic Market segment focuses on the research and development of human parthenogenetic stem cells for the treatment of diseases of the central nervous system, liver diseases and is currently conducting clinical trials for the treatment of Parkinson's disease. The company was founded by William B. Adams, Kenneth C. Aldrich and Gregory S. Keller on August 17, 2001 and is headquartered in Carlsbad, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.21 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











International Stem Cell (OTCMKTS:ISCO) Frequently Asked Questions

What stocks does MarketBeat like better than International Stem Cell?

Wall Street analysts have given International Stem Cell a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but International Stem Cell wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting International Stem Cell?

International Stem Cell saw a increase in short interest in August. As of August 31st, there was short interest totaling 1,000 shares, an increase of 100.0% from the August 15th total of 500 shares. Based on an average daily trading volume, of 10,100 shares, the days-to-cover ratio is currently 0.1 days.
View International Stem Cell's Short Interest
.

When is International Stem Cell's next earnings date?

International Stem Cell is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for International Stem Cell
.

How were International Stem Cell's earnings last quarter?

International Stem Cell Co. (OTCMKTS:ISCO) posted its quarterly earnings results on Friday, August, 13th. The biotechnology company reported ($0.06) EPS for the quarter. The biotechnology company earned $1.83 million during the quarter.
View International Stem Cell's earnings history
.

How has International Stem Cell's stock been impacted by Coronavirus?

International Stem Cell's stock was trading at $0.5850 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ISCO stock has decreased by 4.3% and is now trading at $0.56.
View which stocks have been most impacted by COVID-19
.

Who are International Stem Cell's key executives?

International Stem Cell's management team includes the following people:
  • Andrey Semechkin, Co-Chairman & Chief Executive Officer
  • Sophia Garnette, Chief Financial Officer & VP-Legal Affairs
  • Russell Kern, Director, Chief Scientific Officer & Executive VP

What other stocks do shareholders of International Stem Cell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other International Stem Cell investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Athersys (ATHX), Turkcell Iletisim Hizmetleri A.S. (TKC), Biocept (BIOC), Capricor Therapeutics (CAPR), (CGC), Neuralstem (CUR), FuelCell Energy (FCEL) and Gulf Keystone Petroleum (GKP).

What is International Stem Cell's stock symbol?

International Stem Cell trades on the OTCMKTS under the ticker symbol "ISCO."

How do I buy shares of International Stem Cell?

Shares of ISCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is International Stem Cell's stock price today?

One share of ISCO stock can currently be purchased for approximately $0.56.

How much money does International Stem Cell make?

International Stem Cell has a market capitalization of $4.48 million and generates $7.13 million in revenue each year.

How many employees does International Stem Cell have?

International Stem Cell employs 34 workers across the globe.

What is International Stem Cell's official website?

The official website for International Stem Cell is www.internationalstemcell.com.

Where are International Stem Cell's headquarters?

International Stem Cell is headquartered at 5950 PRIESTLY DRIVE, CARLSBAD CA, 92008.

How can I contact International Stem Cell?

International Stem Cell's mailing address is 5950 PRIESTLY DRIVE, CARLSBAD CA, 92008. The biotechnology company can be reached via phone at (760) 940-6383 or via email at [email protected].


This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.